A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX

Trial Profile

A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Pexastimogene devacirepvec (Primary) ; Cyclophosphamide
  • Indications Advanced breast cancer; Soft tissue sarcoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms METROmaJX
  • Most Recent Events

    • 12 Apr 2017 According to a Transgene media release, results of the Phase 1 part of the study will be presented at upcoming scientific congresses.
    • 12 Apr 2017 According to a Transgene media release, the first patient with soft tissue sarcoma (STS) has been treated in the Phase 2 part of this trial.
    • 27 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top